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In this study, three kinds of phenothiazine drugs were analyzed to explore their potential antitumor mechanisms. First, target 
proteins that could interact with chlorpromazine, fluphenazine and trifluoperazine were predicted. Then, the target proteins of 
the three drugs were intersected. Cell signaling pathway enrichment and related disease enrichment were conducted for the in-
tersected proteins to extract the enrichment categories associated with tumors. By regulation network analysis of the protein 
interactions, the mechanisms of action of these target proteins in tumor tissue were clarified, thus confirming the potential an-
titumor mechanisms of the phenothiazine drugs. The final results of cell signaling pathway enrichment and related disease en-
richment showed that the categories with the highest score were all found in tumors. Target proteins belonging to the tumor 
category included signaling pathway members such as Wnt, MAPK and retinoic acid receptor. Moreover, another target pro-
tein, MAPK8, could indirectly act on target proteins CDK2, IGF1R, GSK3B, RARA, FGFR2 and MAPK10, thereby affecting 
tumor cell division and proliferation. Therefore, phenothiazine drugs may have potential antitumor effects, and tumor-     
associated target proteins play important roles in the process of cell signaling transduction cascades. 
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There are many types of antitumor chemotherapy drugs. 
According to the traditional classification system, they can 
be divided into alkylating agents, antimetabolites, antitumor 
antibiotics, plant-based, hormones and miscellaneous drugs. 
In turn, according to the effects of drugs on cell prolifera-
tion kinetics, they can be divided into cell cycle-specific 
drugs and cell cycle non-specific drugs. However, chemo-
therapy drugs have more side effects, such as nausea, vom-
iting, hair loss and pain, so many cancer patients undergo 
great suffering during this type of treatment. Phenothiazine 
drugs are relatively stable and widely used anti-psychotic 
drugs that mainly act on central dopamine receptors and 
have sedative, antiemetic, anti-psychotic and body temper-
ature-lowering effects. Their representative drug is chlor-
promazine. Studies have found that chlorpromazine can 
enhance the cytotoxic effects of tamoxifen on breast cancer 
[1]. Phenothiazine drugs can also enhance the sensitivity of 
chemotherapy drugs such as cisplatin [2], and reverse re-
sistance of tumor cells to chemotherapeutic drugs [3]. These 
results are indicative of the characteristics of their adjuvant 
chemotherapy. Other reports show chlorpromazine can spe-
cifically inhibit mitotic kinesin KSP/Eg5 to cause mitotic 
arrest, further inhibiting tumor cell proliferation [4], and can 
selectively exert cytotoxic effects on lymphoblastoid tumor, 
neuroblastoma, non-small-cell lung cancer and breast can-
cer cells relative to normal cells [5]. In studies of phenothi-
azine drugs to treat leukemia and lymphoma cells, it has 
been reported that a commonly used clinical dose of chlor-
promazine and trifluoperazine can promote apoptosis in 
leukemia and lymphoma without affecting normal cells [6]. 
These evidences indicate that this type of drug can inhibit 
tumor proliferation. Previous studies have also found that 
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phenothiazine drugs can inhibit tumor proliferation [7], and 
the probability of patients with schizophrenia developing 
cancer is lower than that of normal people [7,8], showing 
the potential antitumor effects of these drugs. Since pheno-
thiazine drugs have varying degrees of antiemetic, sedative 
and analgesic effects, they may be able to reduce the side 
effects of chemotherapy, and they themselves also have a 
role in inhibiting tumor cell proliferation. These drugs can 
also reduce anxiety, insomnia and other symptoms related to 
the psychological state of cancer patients. Chlorpromazine 
was discovered in 1952, and has broad antitumor application 
prospects because of its common use and specific side effects. 
In this study, chlorpromazine and its derivatives, fluphena-
zine and trifluoperazine (Figure 1), were selected to predict 
drug target proteins. The tumor-associated target proteins that 
these drugs might act upon were further analyzed to clarify 
the possible antitumor mechanisms of these drugs. 
1  Materials and methods 
1.1  Screening of antitumor drugs 
First, lung cancer gene expression profiling data 
(GSE10072 and GSE31210) and breast cancer gene expres-
sion profiling data (GSE29431 and GSE14548) were 
downloaded from the GEO Public Expression Profiling Da-
tabase in National Center for Biotechnology Information 
(NCBI) [9]. Lung cancer is closely correlated with smoking, 
so lung tissue data associated with smoking were selected 
from lung cancer expression profile data. GSE10072 ex-
pression profile data included 34 normal lung tissues and 42 
lung cancer tissues of patients who smoked. GSE31210 
expression profile data included 12 normal lung tissues and 
111 lung cancer tissues of patients who smoked. For the 
breast cancer expression profiles, GSE29431 data contained 
12 normal breast tissues and 54 breast cancer tissues, and 
GSE14548 data contained 28 normal breast tissues and 38 
breast cancer tissues. In the same expression profile, differ-
entially expressed genes of normal tissues and tumor tissues 
were screened using Bonferroni correction [10]; results with 
P-values of <0.05 were selected. After screening, addition- 
al genes were screened from lung cancer tissues, so the 
conditions were further limited: changes in normal and tu-
mor gene expression values were increased by two-fold. 
The expression profiles of both lung cancer and breast can-
cer contained two groups of expression profiling data sub-
mitted from different laboratories, so screened differentially 
expressed genes were intersected. Ninety-seven intersected 
genes were upregulated and 234 intersected genes were 
downregulated in lung cancer tissue compared with normal 
lung tissue, while 37 intersected genes were upregulated 
and 53 intersected genes were downregulated in breast can-
cer tissues compared with normal breast tissues. Differen-
tially expressed gene-related drug enrichment analysis was 
converted to be conducted on intersected genes screened as 
described above using an Affymetrix U133A [11] probe and 
connectivity map [12]. The connectivity map was used to 
record the changing expression pattern profiles of tumor 
cells treated with a large number of small-molecule drugs; 
this screening tool was capable of matching expression pro-
files and chemotherapy drugs. Using this tool, tu-
mor-associated small-molecule drugs could be screened by 
changes in tumor tissue expression profiles. According to 
these results, enriched fraction-negative drugs could reverse 
the expression direction of those expression profiles in-
putted. Inputted expression profile data included upregulat-
ed and downregulated differentially expressed genes, and 
the screened drugs could reverse this expression profiling 
mode, thus also potentially suppressing tumor occurrence 
and development. Therefore, drugs that enriched fractions 
were negative; P-values less than 0.05 and the number of 
experiments of compound taking effects on cells was larger 
than 8 were selected in the analysis. Enrichment fraction 
was negative, indicating that the compounds screened out 
had negative correlation with input expression profile. 
P<0.05 and eight experiments of compounds on cells all  
 
 
Figure 1  Molecular structures of three kinds of phenothiazine drugs. The main structures of the three types of phenothiazine drugs are basically similar, 
while the side-chain radicals are different. Fluphenazine and trifluoperazine are all derivatives of chlorpromazine. 
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suggested high validation. From the above analysis, we 
found that chlorpromazine, fluphenazine and trifluoperazine 
might have potential antitumor effects. 
1.2  Mechanism of action of phenothiazine drugs 
The DOCK6 database can simulate the docking of com-
pounds and protein molecules to predict target proteins ca-
pable of interacting with compounds. Using DRAR-CPI (a 
server for predicting Drug Repositioning and Adverse Re-
action via Chemical-Protein Interactome) [13] with DOCK6, 
target proteins capable of interacting with chlorpromazine, 
fluphenazine and trifluoperazine were predicted. The pre-
dicted target proteins of the three drugs were intersected to 
aggregate the target proteins that might be able to interact 
with all three drugs. Then, enrichment analysis was con-
ducted on these target proteins through DAVID (Database 
for Annotation, Visualization and Integrated Discovery) [14] 
using the KEGG pathway database and gene-related disease 
classification database. Tumor-associated target proteins 
were taken from the enrichment result and protein interac-
tion network analysis was conducted using the Gene-
MANIA [15] and Visant tools (Integrative Visual Analysis 
Tool for Biological Networks and Pathways) [1618]. Cell 
signaling regulatory networks in which these target proteins 
were involved were analyzed, thus indicating the method by 
which the three drugs inhibit tumor cell proliferation. By 
matching the inputted genes in the database using DAVID, 
these genes were enriched in different categories according 
to various databases. GeneMANIA is a tool for rapid pre-
diction of protein function, and can integrate multiple ge-
nomes and proteome data to infer proteins of unknown 
function. This tool can identify a plurality of protein func-
tions by integrating information. Therefore, protein func-
tion-related modules in networks can be quickly found by 
using it to further tap the biological significance of the net-
work. In contrast, the Visant tool mainly analyzes protein 
interactions to build networks using published protein in-
teraction data.  
2  Results 
2.1  Screening results of antitumor drugs 
Screening revealed that of the relevant drugs eventually 
selected against breast cancer (Table 1) and lung cancer 
(Table 2), chlorpromazine, fluphenazine and trifluoperazine 
belonged to the phenothiazine group of drugs, and fluphen-
azine and trifluoperazine were derivatives of chlorproma-
zine; the number of compounds having an effect on cells (n 
value) was high, indicating the results were relatively relia-
ble. Subsequently, similar results were also obtained using 
the same method for expression profiles of colorectal cancer, 
indicating that these drugs probably had potential antitumor 
properties, consistent with previously reported findings. 
Thus we were confident that it provided a reliable basis for  
Table 1  Ten drugs with potential antitumor effects in breast cancer based 
on expression profilinga) 
Drug Mean n Enrichment P 
Prochlorperazine 0.562 16 0.477 0.00076 
Chlorpromazine 0.476 19 0.416 0.00168 
Trifluoperazine 0.439 16 0.426 0.00383 
Resveratrol 0.541 9 0.537 0.0058 
Deferoxamine 0.458 8 0.541 0.01019 
0179445-0000 0.445 8 0.534 0.01161 
Alpha-estradiol 0.458 16 0.376 0.01558 
Fluphenazine 0.379 18 0.346 0.02103 
Methotrexate 0.44 8 0.478 0.0338 
Thioridazine 0.437 20 0.302 0.03949 
a) All n-values of the three phenothiazine drugs shown in Table 1 are 
relatively high, and all P-values are less than 0.05, indicating they are 
likely to be associated with breast cancer. 
Table 2  Ten drugs with potential antitumor effects in lung cancer scree- 
ning based on expression profilinga) 
Drug Mean n Enrichment P 
Trichostatin A 0.432 182 0.279 0 
Chlorpromazine 0.449 19 0.46 0.00036 
LY-294002 0.394 61 0.257 0.0005 
Vorinostat 0.552 12 0.515 0.00166 
Resveratrol 0.554 9 0.554 0.00368 
Alpha-estradiol 0.48 16 0.397 0.00874 
Tanespimycin 0.327 62 0.201 0.01244 
Fluphenazine 0.358 18 0.36 0.01443 
Thioridazine 0.362 20 0.303 0.0384 
Trifluoperazine 0.346 16 0.334 0.04225 
a) All n-values of the three phenothiazine drugs shown in Table 2 are 
relatively high, and all P-values are less than 0.05, indicating they are 
likely to be associated with lung cancer. 
 
the subsequent analysis. 
2.2  Predicting results of target proteins 
The target proteins of the three phenothiazine drugs were 
predicted using DRAR-CPI. These were calculated when 
the interaction strength of the drugs with target proteins 
reached a Z-score of less than 0.5 (combined with stand-
ardized score of strength). Ninety-eight target proteins that  
might be able to interact with chlorpromazine were predict-
ed; 91 target proteins with fluphenazine and 117 target pro-
teins with trifluoperazine. The three groups of target pro-
teins described above were intersected, and a total of 39 
target proteins that were likely to interact with all three 
types of phenothiazine drugs were obtained, thus improving 
the specificity of the interacting proteins. 
2.3  Enrichment of tumor-associated target proteins 
Enrichment analysis was conducted on the above-described 
39 target proteins using the DAVID gene-related disease  
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Table 3  Related disease enrichment of common target proteins of the three drugsa) 
Category Term Count P-value 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS CANCER 13 0.001877 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS AGING 5 0.00578 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS REPRODUCTION 6 0.023581 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS DEVELOPMENTAL 6 0.026687 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS METABOLIC 11 0.038986 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS OTHER 10 0.054997 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS PHARMACOGENOMIC 6 0.068428 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS PSYCH 8 0.072443 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS HEMATOLOGICAL 4 0.073614 
GENETIC_ASSOCIATION_DB_DISEASE_CLASS NEUROLOGICAL 8 0.086108 
a) It can be seen from the enrichment results that tumor type shows the highest degree of significant association. 
classification database. The results showed that the most 
relevant class was tumors, indicating that these target pro-
teins were involved in tumor-associated biological process-
es (Table 3). Moreover, these phenothiazine drugs might be 
able to directly act on these target proteins, indicating that 
they could influence the occurrence and development of 
tumors. Pathway enrichment analysis was conducted on the 
target genes referred to above using the KEGG pathway  
database; tumor-related signaling pathways also showed the 
highest degree of association. Nine tumor-associated target 
proteins constituted this signaling pathway, namely CDK2, 
FGFR2, GSK3B, IGF1R, MAPK10, MAPK8, PPARG, 
RARA and RXRA (Table 4). CDK2 is a cell cycle-    
dependent protein kinase that participates in the regulation 
of the cell cycle, cell mitosis and phosphorylation of other 
tumor-associated proteins, and is thus closely associated 
with tumor growth. FGFR2 is an evolutionarily conserved 
fibroblast growth factor receptor involved in the regulation 
of cell proliferation, differentiation, migration and apoptosis, 
and embryonic development, and can mediate and activate 
the MAPK signaling pathway. FGFR2 overexpression can 
promote cell transformation and neoplasia. GSK3B, a gly-
cogen synthase kinase with serine/threonine protein kinase 
activities, is an important molecule in the Wnt signaling 
pathway, which plays an important role in tumor develop-
ment. IGF1R is an insulin-like growth factor receptor with 
tyrosine kinase activity that is overexpressed in most ma-
lignant tumors. It has anti-apoptotic effects and enhances 
cell survival. Both MAPK10 and MAPK8 belong to the 
mitogen-activated protein kinase family and are involved in 
a variety of cellular and molecular processes, including pro-
liferation, differentiation, transcription regulation and de-
velopment. They are also very closely related to tumors. 
PPARG is a member of the peroxisome proliferator-   
activated receptor family and is involved in the regulation 
of adipocyte differentiation and glucose homeostasis. It is 
associated with various diseases, including obesity, diabetes, 
atherosclerosis and cancer. Studies have shown that PPARG 
is an independent marker for a good prognosis of colorectal 
cancer [19], and many studies have shown it has antitumor 
properties [20]. Both RARA and RXRA are important 
members of the retinoic acid signaling pathway and belong 
to the RARs and RXRs nuclear receptor families, respec-
tively. RARA and RXRA play important roles in tumor 
genesis and development, which provide target point for 
chemotherapy drugs such as retinoic acid and are closely 
related to the efficiency of chemotherapy [21]. Therefore, 
they have been shown to be correlated with tumor chemo-
therapy. RARA can combine with RXRA to form a hetero-
dimer involved in gene transcription and expression, while 
PPARG can also form a heterodimer with RXRA with sim-
ilar functions [22]. Thus, PPARG, RARA and RXRA are 
closely linked in function. 
2.4  Analysis of network regulation of tumor-associated 
target protein interactions 
Network regulation analyses of protein interactions were 
conducted on the nine target proteins associated with tumor 
signaling pathways using GeneMANIA, as described above. 
It was found that 38.25% of target proteins and their inter-
acting proteins have the same protein domain, indicating 
that these target proteins might have some similar functions 
in the tumor-associated signaling pathways, or are function-
ally interrelated. CDK2 and RARA proteins could co-  
localize, and MAPK8, MAPK10, RARA, RXRA, PPARG, 
FGFR2 and their interacting proteins had co-expression  
Table 4  Target proteins associated with tumor-associated signaling 
pathways 
Gene symbol Gene name 
CDK2 Cyclin-dependent kinase 2 
FGFR2 Fibroblast growth factor receptor 2 
GSK3B Glycogen synthase kinase 3 beta 
IGF1R Insulin-like growth factor 1 receptor 
MAPK10 Mitogen-activated protein kinase 10 
MAPK8 Mitogen-activated protein kinase 8 
PPARG Peroxisome proliferator-activated receptor gamma 
RARA Retinoic acid receptor, alpha 
RXRA Retinoid X receptor, alpha 
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Figure 2  Tumor-associated target protein interactions. Black protein nodes indicate tumor-associated target proteins, while the gray nodes indicate target 
protein-related proteins; different connecting colors represent different correlations. 
 
Figure 3  Network regulation of tumor-associated target protein interactions. Red nodes represent tumor-associated target proteins that could be affected by 
all three drugs, and blue nodes indicate the proteins that can interact with target proteins. Connecting lines between protein nodes represent the interactions 
among proteins. A connecting line with two or more colors illustrates the connection among proteins as supported by multiple experimental evidence. 
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characteristics, further suggesting that these proteins have a 
common function. From the results of the network regula-
tion of protein interactions, network modules composed of 
RARA, RXRA, PPARG and their interacting proteins were 
functionally closely linked, being possible key target pro-
teins of phenothiazine drugs in the tumor cells. Furthermore, 
functional classes composed of this network module partic-
ipate in retinoic acid signal transduction and may have cer-
tain correlations with cancer chemotherapy, further indicat-
ing that phenothiazines could enhance the antitumor prop-
erty of chemotherapy drugs with auxiliary antitumor effects. 
To further understand the effects of the nine identified 
target proteins associated with tumor signaling pathways, 
further analysis of interaction network regulation was con-
ducted using the Visant tool. First, the target proteins were 
imported into Visant and the interacting proteins of each 
target protein were retrieved to identify any connections. 
Then, all network circuits among these nine target proteins 
were calculated, protein nodes that were not in circuits were 
removed, and signaling regulation networks dominated by 
these nine target proteins were obtained; by calculation, 
there were 128 protein nodes in the circuits. Enrichment 
analysis of the biological processes and molecular functions 
was conducted on the protein nodes in these circuits using 
WebGestalt. The results showed most of these 128 proteins 
have regulatory functions and are involved in metabolic 
processes and biological processes such as response to ex-
ternal stimuli, confirming these proteins are primarily in-
volved in cell signal transduction. Therefore, the molecular 
function enrichment revealed that most of the proteins have 
binding functions; several proteins have nucleic acid bind-
ing abilities and transcriptional regulatory activity, indicat-
ing they are transcription factors. To specify how these pro-
teins conduct cell signal transduction, re-combination of 
signal cascade regulation was conducted on these proteins 
to produce a network diagram of possible signal transduc-
tion regulation (Figure 3). From this, it appears that PPARG 
protein regulates MAPK8 protein. MAPK8 can directly 
affect 60 protein nodes in the upper layer, while these 60 
protein nodes can affect six tumor-associated target proteins, 
which in turn can act upon 69 protein nodes in the lower 
layer, respectively. Of the 69 protein nodes, RXRA can be 
directly affected by RARA and GSK3B. This is a possible 
signal transduction cascade model that can specify how tar-
get proteins affect the signal transduction process; hence the 
molecular events in which the 60 blue protein nodes on the 
upper layer and the 69 blue protein nodes on the lower layer 
participated were analyzed further using GATHER (Gene 
Annotation Tool to Help Explain Relationships) [23]. The 
upper 60 protein nodes were mainly involved in the MAPK 
signaling pathway, and some protein nodes were also in-
volved in apoptosis and cell cycle-related molecular events 
(Table 5), while the lower 69 protein nodes were mainly 
involved in cell metabolism, cell proliferation, gene tran-
scription, mitosis and other cell proliferation-related molec-
ular events (Table 6). From signal transmission to the final 
regulation of cell proliferation, the acting sites of three 
phenothiazine drugs were all important nodes in the process 
of cellular signal transduction, illustrating the critical role of 
the targets of these drugs in tumor development.
Table 5  Molecular events of the upper 60 blue protein nodes 
Enrichment of biological processes of proteins on the upper layer Number of proteins 
GO:0000165: MAPKKK cascade 7 
GO:0007254: JNK cascade 5 
GO:0007243: protein kinase cascade 9 
GO:0006915: apoptosis 10 
GO:0050794: regulation of cellular process 13 
GO:0008629: induction of apoptosis by intracellular signals 3 
GO:0007049: cell cycle 12 
GO:0000074: regulation of cell cycle 9 
GO:0007242: intracellular signaling cascade 14 
Table 6  Molecular events of the lower 60 blue protein nodes 
Enrichment of biological processes of proteins on the lower layer Number of proteins 
GO:0006366: transcription from Pol II promoter 15 
GO:0044238: primary metabolism 54 
GO:0007049: cell cycle 17 
GO:0000074: regulation of cell cycle 12 
GO:0008283: cell proliferation 19 
GO:0044237: cellular metabolism 53 
GO:0006350: transcription 26 
GO:0000910: cytokinesis 7 
GO:0006351: transcription, DNA-dependent 25 
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3  Discussion 
In this study, chemotherapy drugs related to breast cancer 
and lung cancer were selected based on differentially ex-
pressed genes identified through gene expression profiling; 
from this, we distinguished three phenothiazine drugs that 
may be able to inhibit breast cancer and lung cancer. Phe-
nothiazine drugs are proposed to have potential antitumor 
effects, and similar results have been shown in colorectal 
cancer. In this study, the possible antitumor mechanisms of 
three phenothiazine drugs, chlorpromazine, fluphenazine 
and trifluoperazine, were further explored using bioinfor-
matics methods. The target proteins of these drugs were 
predicted and found to be closely related to tumor-     
associated cell signaling. These proteins were further stud-
ied to construct regulatory protein networks using two net-
work-building tools. Results of the GeneMANIA analysis 
showed that phenothiazine drugs may be able to act on sig-
naling pathway members such as Wnt, MAPK and retinoic 
acid in tumor cells. All these target proteins are closely as-
sociated with tumors. A network module composed of 
RARA and RXRA target proteins may be relatively im-
portant. Because these target proteins are involved in retin-
oic acid signal transduction, they may be significant in 
chemotherapy. Through the Visant tool, the network de-
scribed above was further refined and a model of the signal 
transduction cascade was constructed. From this, it can be 
seen that the target protein MAPK8 can indirectly impact 
upon target proteins CDK2, IGF1R, GSK3B, RARA, 
FGFR2 and MAPK10 through its interacting proteins, and 
these target proteins can directly affect cell proliferation, 
division and growth (Figure 4); thus, during signal trans-
duction, the effects on some important nodes can further 
amplify the signals to alter the biological behaviors of the 
cells. However, whether protein interactions are promoted 
or inhibited requires further study. Because the mechanistic 
effects of the drugs on cell signaling are more complex, 
screening and analysis were conducted using a variety of 
methods in this study to improve the reliability of our con-
clusions. First, during the screening of tumor-associated 
chemotherapy drugs, phenothiazine drugs were found to 
have a high correlation with lung cancer, breast cancer and 
colorectal cancer, and in the analysis of the target proteins, 
because the molecular structures of three drugs are similar, 
the intersections of target proteins of three drugs were se-
lected to improve the accuracy of the target proteins identi-
fied. Then, in the selection of the target proteins, those with 
strong interactions were selected for the intersection analy-
sis. In the network regulation analysis of the target proteins, 
two tools were selected. These methods can be used to ob-
tain more accurate conclusions and get a better handle on 
the antitumor mechanisms of phenothiazine drugs. Few 
studies have been conducted on the antitumor effects of 
phenothiazine drugs; therefore, this article provides new  
 
Figure 4  Possible antitumor mechanisms of three types of phenothiazine 
drugs. Tumor-associated signaling cascade as determined by bioinformat-
ics analysis. Phenothiazine drugs might be able to interact with the identi-
fied protein nodes to inhibit the occurrence and development of tumors. 
evidence for the antitumor effects of phenothiazine drugs. 
Of the phenothiazine drugs, chlorpromazine was discovered 
first. It can block dopamine receptors and has sedative, an-
tiemetic and analgesic effects. As with other drugs, these 
kinds of drugs also have some adverse reactions such as dry 
mouth, fatigue, drowsiness, constipation and palpitations. A 
large quantity or long-term application of these drugs can 
cause extrapyramidal symptoms. However, because of the 
different functions of this drug, dosages are also incon-
sistent. Therefore, we should weigh up the advantages and 
disadvantages of their clinical use, and conduct close moni-
toring and dosage control to reduce the incidence of adverse 
reactions. The treatment of cancer is an important medical 
issue. Early tumor symptoms are often not obvious, causing 
many patients to present with distant organ metastasis upon 
diagnosis. Therefore, chemotherapy is an important means 
for treating tumors, particularly for patients with broad me-
tastasis who are unsuitable candidates for surgery. However, 
the low specificity of chemotherapy drugs often results in 
unpleasant side effects. In this study, the potential antitumor 
mechanisms of three types of phenothiazine drugs were 
studied. This information may enable these drugs to be used 
rationally in tumor chemotherapy to reduce side effects and 
improve patient tolerance, thereby enhancing the inhibition 
efficiency of tumors and improving survival rates. 
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